Citicoline Concentration in Human Vitreous

Status Completed

Clinical Trial Summary

Elegible patients were included in the study and underwent treatment with a solution of citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride prior to surgery. The vitreous samples were taken at the beginning of the surgery and analyzed for qualitative/quantitative determination of vitreous concentration of citicoline and its metabolites by means of high performance liquid chromatography.

Clinical Trial Description

At the visit all patients underwent comprehensive ophthalmological examination including best corrected visual acuity assessment, slit lamp evaluation, IOP measurement using Goldmann applanation tonometry, and fundus dilated indirect ophthalmoscopy.

Additionally, all patients had central retinal thickness measurements with spectral-domain optical coherence tomography associated with central corneal thickness (CCT) and corneal endothelial cells density (ECD) evaluations.

Patients started the treatment with 1 drop of a solution of citicoline 1% eye-drops, 0.2% hyaluronic acid and 0.01% benzalkonium chloride for 3 times/day over a total time of 14 days before surgery and 1 drop 2 hours prior to the surgery.

Five patients served as controls and received a vehicle solution without citicoline.

The primary aim of the study was to evaluate the presence and concentration of citicoline and its metabolites (choline, cytidine and uridine) in the vitreous body in vivo in human eyes after topical eye-drops administration by means of high performance liquid chromatography.

Secondary aims were the comparison of citicoline and its metabolites concentration in the vitreous of treated phakic and pseudophakic eyes and the correlations with age and ocular biometric parameters including CCT and ECD. ;

Study Design

Related Conditions & MeSH terms

Neurodegenerative Diseases

Clinical Trial Details

NCT number	NCT04003090
Study type	Interventional
Source	Istituto di Ricerca Neuroftalmologia S.r.l.
Contact
Status	Completed
Phase	N/A
Start date	March 21, 2018
Completion date	January 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05538455` - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases	N/A
Completed	`NCT05788133` - The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training.	N/A
Completed	`NCT05080777` - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems	N/A
Completed	`NCT03295786` - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease	Phase 1/Phase 2
Recruiting	`NCT04265482` - Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
Not yet recruiting	`NCT02222779` - Quantification of Transition Metals	N/A
Recruiting	`NCT01291550` - Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples	N/A
Completed	`NCT01450891` - Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease	N/A
Completed	`NCT01953523` - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions	N/A
Recruiting	`NCT06148233` - CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging	N/A
Completed	`NCT03538522` - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831	Phase 2
Completed	`NCT06251830` - Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
Recruiting	`NCT04472130` - Neurodegenerative Diseases Registry
Completed	`NCT03353207` - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed	`NCT05095870` - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Recruiting	`NCT05784090` - Correlation Between Melatonin Levels in Different Biological Fluids
Completed	`NCT02108769` - Yogic Breathing Changes Salivary Components	N/A
Recruiting	`NCT05508789` - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	Phase 3
Recruiting	`NCT05235802` - Long-term Follow-up in Severe Traumatic Brain Injury
Recruiting	`NCT04820881` - Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury